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Abstract
Background:  Procalcitonin (PCT) has been proposed as a diagnostic and prognostic sepsis
marker, but has never been validated in febrile patients with prolonged ICU stay.
Methods: Patients were included in the study provided they were hospitalised in the ICU for > 10
days, were free of infection and presented a new episode of SIRS, with fever >38°C being
obligatory. Fifty patients fulfilled the above criteria. PCT was measured daily during the ICU stay.
The primary outcome was proven infection.
Results: Twenty-seven out of 50 patients were diagnosed with infection. Median PCT on the day
of fever was 1.18 and 0.17 ng/ml for patients with and without proven infections (p < 0.001). The
area under the curve for PCT was 0.85 (95% CI; 0.71-0.93), for CRP 0.65 (0.46-0.78) and for WBC
0.68 (0.49-0.81). A PCT level of 1 ng/mL yielded a negative predictive value of 72% for the presence
of infection, while a PCT of 1.16 had a specificity of 100%. A two-fold increase of PCT between
fever onset and the previous day was associated with proven infection (p 0.001) (OR = 8.55; 2.4-
31.1), whereas a four-fold increase of PCT of any of the 6 preceding days was associated with a
positive predictive value exceeding 69.65%. A PCT value less than 0.5 ng/ml on the third day after
the advent of fever was associated with favorable survival (p 0.01).
Conclusion: The reported data support that serial serum PCT may be a valuable diagnostic and
prognostic marker in febrile chronic critically ill patients.
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Background
An increasing proportion of critically ill patients require
prolonged intensive care unit (ICU) stay [1]. It is not
unexpected that this group of patients is associated with
increased risk for all kind of complications, adverse short-
term outcomes, and increased consumption of ICU
resources with infectious complications being always at
the center of the discussion in this setting [2]. Although
survivors of prolonged ICU stays have good long-term
mortality outcome, ICU mortality remains high and
severely affected by sepsis and its complications [3]. The
presence of nosocomial infection and the number of
infection episodes have been identified as the variables
with the strongest association with prolonged hospital
stay among ICU patients [4], and the effect of the most
common ICU infections on duration of ICU stay has been
well documented [5,6].
Patients with prolonged ICU stay are prone to be colo-
nized and infected by multi-drug resistant bacteria. Fur-
thermore these patients have often their metabolic and
neurohormonal reserves exhausted, while their immune
response might be severely affected [7]. The combination
of the above makes the identification of a new infectious
episode quite often a clinical challenge, while on the other
hand these patients have many reasons to develop a sys-
temic inflammatory response not associated with infec-
tion. Every intensivist is constantly dealing with these
'grey-zone' cases, fearing delayed diagnosis and treatment
of a new infection on one hand, and excess antibiotic use,
multi-resistance, and increased costs on the other.
Procalcitonin (PCT) has been proposed as a marker to dif-
ferentiate sepsis from other non-infectious causes of SIRS.
After the initial enthusiasm, many studies have provided
conflicting results on the diagnostic accuracy of PCT in
different patient settings including critically ill patients
[8,9], and have highlighted the importance of integrating
laboratory and clinical evaluation. On the other hand,
PCT has been shown capable to guide antibiotic use in
lower respiratory tract infection [10], community-
acquired pneumonia [11] and, recently, in critically ill
patients with sepsis [12].
Even though recently published studies [13,14] con-
ducted in single centers with selected patient populations
have shown the diagnostic value of PCT monitoring in the
ICU setting, confirmatory research is urgently needed
before the widespread adoption of this practice. In addi-
tion, it is unclear if the diagnostic accuracy of PCT dimin-
ishes in prolonged need for critical care probably due to
intercurrent confounding conditions. Finally, the poten-
tial prognostic value of PCT measurements in this partic-
ular patient population has not been thoroughly studied.
The aim of the present study is to evaluate prospectively
the diagnostic accuracy of PCT in ICU patients with pro-
longed stay (defined by an ICU length of stay ≥ 10 days),
to compare it with other commonly used laboratory and
clinical markers and to examine the value of serial PCT
measurements in this setting.
Methods
This observational cohort study was performed in accord-
ance with the Declaration of Helsinki and was approved
by the 'Attikon' University Hospital's review board.
Informed consent was obtained from the patient's next of
kin. All patients hospitalized in the ICU of Attikon Uni-
versity Hospital between November 1st 2007 and April
30th 2008 were assessed for eligibility and had their circu-
lating PCT levels prospectively measured daily as long as
they stayed in the ICU. Patients were included in the study
provided they 1) were hospitalised in the ICU for more
than 10 days, 2) were considered free of infection on
admission to the study according to the evaluation of the
treating physician and 3) presented a new episode of SIRS,
with fever >38°C being an obligatory criterion.
Demographic data, comorbidities and clinical parameters
including microbiology data were recorded upon study
enrollment. Patients were considered as being colonized
with multi-drug resistant (MDR) pathogens if at least one
multi-drug resistant strain was isolated at the last anal
swab or tracheal aspirate screening which is routinely per-
formed twice weekly in our ICU. MDR bacteria were
defined as methicillin-resistant Staphylococcus aureus or for
Gram-negative bacilli, resistant against at least to two dif-
ferent classes of antibiotics such as penicillins (+beta-
lactamase inhibitor), third-generation cephalosporins,
fluoroquinolones or carbapenems. Severity indexes,
including Acute Physiology and Chronic Health Evalua-
tion (APACHE) II and Sequential Organ Failure Assess-
ment (SOFA) scores were calculated at baseline, while
SOFA was calculated on a daily basis. SIRS, sepsis, severe
sepsis and septic shock were defined according to SCCM/
ESICM/ACCP/ATS/SIS Consensus Conference [15]. The
primary outcome was proven infection. The diagnosis of
respiratory tract infections, urinary tract infections, blood-
stream infections, and catheter-related infection followed
the Centers for Disease Control definitions [16,17].
Blood samples were collected every morning between
8.00 and 9.00 a.m. Besides routine hematology and bio-
chemistry panels, samples for C-reactive protein (CRP)
and procalcitonin (PCT) were drawn daily. Samples for
PCT were centrifuged at 3000 rpm for 10 minutes, and
sera were stored at -80°C. For serum PCT measurement, a
time-resolved amplified cryptate emission technology
assay was used according to the manufacturer's instruc-
tions (Kryptor, Brahms, Hennigsdorf, Germany). TheBMC Infectious Diseases 2009, 9:213 http://www.biomedcentral.com/1471-2334/9/213
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functional sensitivity of this assay is 0.06 ng/mL. Results
for PCT were not made available to the attending clini-
cians.
Statistics
Continuous variables were compared between the groups
with and without proven bacterial infection by non-para-
metric Mann-Whitney U test. Receiver operator character-
istic (ROC) curves were drawn for PCT, CRP and WBC
count. Repeated measurements were compared between
groups by General Linear Model. Differences with values
of p less than 0.05 were considered statistically significant.
Statistical analysis was performed using SPSS version 13.0
(SPSS Inc., Chicago, Ill).
Results
During the study period 154 patients were screened for
eligibility, and 50 patients fulfilled the inclusion criteria.
The diagnostic work-up revealed 27 patients with proven
infections. The general characteristics of study population
with and without proven infection are shown in Table 1.
Patients with and without proven infection differed signif-
icantly in age and severity of illness; the proportion of
patients suffering a previous septic episode was not differ-
ent between the two groups. WBC count, CRP and PCT in
the groups with and without proven infection are pre-
sented in Table 2. Among the 27 patients with proven
infection, the diagnosis was bloodstream infection in
eight (30%), lung infection in 16 (59%) and abdominal
infection in 3 (11%). Median (interquartile range) PCT
concentrations were 15.7 ng/ml (26.6), 1.0 (2.4) and 1.0
respectively in these three groups. Excluding patients with
blood stream infection, median PCT (IQR) values in
patients without and with proven infection were 0.18
(0.39) and 1.00 (2.69) mg/L respectively (p 0.001).
The area under the ROC curve (95% CI) for PCT was 0.85
(0.71-0.93) (p < 0.0001), for CRP was 0.65 (0.46-0.78) (p
NS) and for WBC count was 0.68 (0.49-0.81) (p 0.01)
(Figure 1). A cut-off value for PCT of 0.15 ng/ml was char-
acterized by sensitivity of 96%, while a cut-off of 1.16 ng/
ml had a specificity of 100% for proven infection. For a
cut-off value of 1 ng/ml, sensitivity was 70%, specificity
91%, and likelihood ratio for a positive test (LR+) was 8.1,
positive predictive value (PPV) of 90% and negative pre-
dictive value (NPV) of 72%.
Median (IQR) PCT concentrations in the group of patients
who survived at 28 days were 0.28 ng/ml (0.80) and in
patients who did not survive were 1.07 (3.09) (p 0.004).
Respective values for CRP were 89.5 (100.4) and 131.0
(106.5) in survivors and non-survivors respectively (p
0.01). Median PCT concentrations sequentially measured
on days 1, 2, 3 and 4 tended to increase in non-survivors
contrary to survivors (p 0.028) (Figure 2). Specifically, a
concentration of PCT less than 0.5 ng/ml on the third day
after the advent of fever was associated with favorable sur-
vival (p 0.01).
PCT values before onset of fever for patients with and
without proven infection are depicted at Figure 3. For the
group with proven infection, the difference between the
PCT value in the day of fever onset and any of the 10 pre-
ceding days was significant (P < 0.001 for any day com-
pared to fever onset day). When patients without proven
infection had their PCT value of the day of fever onset
compared to the PCT of the 5 preceding days, the p value
was 0.023, 0.045, 0.05, 0.013, and 0.030 for days 1, 2, 3,
4, and 5, respectively. A two-fold increase of PCT value
between the day of fever onset and the previous day value
was significantly associated with proven infection (p
0.001) (OR 8.55, 2.4-31.1) (Table 3). Sensitivity, specifi-
city and positive predictive value of a four-fold increase
between any PCT values of the 6 days preceding fever are
shown at Table 4.
Discussion
The main finding of the study was that PCT monitoring
retains its diagnostic value even after a prolonged ICU
stay, as it could differentiate a population of chronic crit-
ically ill patients with microbiologically proven sepsis
from a similar population presenting merely with a new
episode of SIRS and fever without proven infection.
Regarding the primary outcome of proven infection, PCT
performed better than other widely used infection mark-
ers, such as CRP and WBC count, in this population of
patients. Another notable finding was that PCT monitor-
ing possesses not only diagnostic but prognostic informa-
tion as well; in fact, serial PCT measurements
demonstrated an increasing tendency in non-survivors,
while a PCT value of less than 0.5 ng/ml on the third day
after the advent of fever was associated with a favorable
survival outcome. Finally, it is interesting that every PCT
value taken during the days preceding the advent of fever,
and not only the previous day sample, carries potentially
important predictive value. This could mean that serial
PCT values do not need to be obtained on a daily basis,
but twice or three times weekly, a finding with obvious
economic implications.
Differentiating chronic critically ill patients with sepsis
from patients with fever but without sepsis is notoriously
difficult. Infections are not always associated with fever,
the lack of positive culture results cannot exclude infec-
tion, and the traditional definition of SIRS has limited
value because many patients might have SIRS criteria due
to their status, whereas clinical evaluation remains some-
times the only rational approach. It is increasingly clear
that none of the widely used biomarker for sepsis is per-
fect, but PCT performed much better than CRP and WBCBMC Infectious Diseases 2009, 9:213 http://www.biomedcentral.com/1471-2334/9/213
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Table 1: Demographic and clinical data of the patient population
Proven infection
(n = 27)
Unproven infection
(n = 23)
P
Age, years 70 ± 12.1 56 ± 22.1 0.03
Gender (male) 20 (74%) 18 (78%) NS
ICU stay duration until study enrollment 25 ± 12 29 ± 14 NS
APACHE II score on study enrollment 20.5 ± 4.4 15.3 ± 4.1 <0.001
SOFA score on day 1 (Day of fever) 10.1 ± 3 6.2 ± 2.4 0.004
Δ SOFA score 2.7 ± 1.9 0.6 ± 1 <0.001
28-day mortality 15/27 (56%) 7/23 (30%) NS
Day 1 (Day of fever) status
SIRS 1 (4%) 6 (26%) NS
SIRS+New organ failure (besides circulation) 13 (48%) 14 (61%) NS
Shock 13 (48%) 3 (13%) 0.07
Admission category
Respiratory 7 (26%) 6 (26%) NS
Cardiovascular 6 (22%) 3 (13%) NS
Neurological 9 (33%) 10 (43%) NS
Trauma/Surgical 5 (19%) 2 (9%) NS
Co-morbidities
Malignancy 2 (7%) 2 (9%) NS
CRRT 8 (30%) 5 (22%) NS
Steroids 4 (15%) 3 (13%) NS
Previous septic episodes NS
MDR pathogens in the last tracheal aspirate 27/27 (100%) 21/23 (91%) NS
MDR pathogens in the last anal swab 27/27 (100%) 20/23 (87%) NS
Proven infection 17/27(63%) 13/23(56%) NS
Ventilator-associated pneumonia 16 (60%) 0
Bloodstream infection 8 (30%) 0
Abdominal infection 3 (10%) 0
ICU: Intensive Care Unit, APACHE: Acute Physiology and Chronic Health Evaluation, SOFA: System Organ Failure Assessment, ΔSOFA: difference 
between Day 1 (fever) and Day 0 in SOFA score, SIRS: Systemic Inflammatory Response Syndrome, CRRT: Continuous Renal Replacement 
Therapy, MDR: Multi-Drug Resistant.BMC Infectious Diseases 2009, 9:213 http://www.biomedcentral.com/1471-2334/9/213
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count in chronic critically ill. This finding has been shown
in other selected populations [18,19] but to our knowl-
edge has never been demonstrated in chronic critically ill.
In our cohort, PCT on the day of fever was significantly
higher in patients with proven infection compared to the
previous day value, while CRP was not. PCT was signifi-
cantly higher even if we excluded blood stream infections,
demonstrating a good performance in all other infections
as well. A two-fold increase in previous day PCT was asso-
ciated with infection and a four-fold increase of the PCT
value of any of the 6 preceding days was associated with
specificity exceeding 74% and a positive predictive value
exceeding 70% for proven infection. On the other hand a
PCT level of 1 ng/mL yielded a negative predictive value of
72% in our patients, while a PCT of 1.16 ng/ml had a spe-
Table 2: Markers of infection in the groups with and without proven infection and diagnostic validity
No proven infection Proven infection P Sens Spec PPV NPV PLR AUC
Patient
n (%)
23 (46) 27 (54)
WBC count
(109/μ)
-
Median
(IQR)
8.4 (3.4) 14.2 (16.3) 0.03 0.66 0.45 0.76 0.62 2.72 0.68
CRP
(mg/dl)
-
Mean
(SD)
88.3 (64.0) 122.4 (66.6) 0.07 0.59 0.57 0.62 0.54 1.36 0.65
PCT
(mg/L)
-
Median
(IQR)
0.17 (0.39) 1.18 (5.8) <0.001 0.70 0.73 0.75 0.68 2.62 0.85
CRP cut-off: 100; WBC cut-off: 12,000; PCT cut-off: 0.5
PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive Likelihood Ratio, AUC: Area Under Curve, WBC: White Blood Cells, 
IQR: Interquartile Range, CRP: C- reactive protein, SD: Standard Deviation, PCT: Procalcitonin.
ROC curves for PCT, CRP and WBC count for differentia- tion between proven and not-proven infections Figure 1
ROC curves for PCT, CRP and WBC count for differ-
entiation between proven and not-proven infections. 
ROC: receiver operator characteristics, PCT: Procalcitonin, 
CRP: C- reactive protein, WBC: White Blood Cells.

Trend of PCT concentrations on sequential daily measure- ments between days 1 and 4 in patients with and without  favorable outcome at 28 days Figure 2
Trend of PCT concentrations on sequential daily 
measurements between days 1 and 4 in patients with 
and without favorable outcome at 28 days. PCT: Pro-
calcitonin.
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cificity of 100%. Different PCT cut-off values in medical
and surgical critically ill patients, not only at the ICU
admission but also during the entire ICU stay have been
demonstrated previously [20] and the need for cut-off
points tailored to certain populations and conditions is
increasingly recognized. Even previous episodes of sepsis,
a common finding in chronic critically ill patients, seem
to affect PCT performance [21]. Recent studies have
upgraded the significance of PCT in guiding antibiotic
use, based on its negative predictive value and the
assumption that a patient with a low PCT does not have
bacterial sepsis [10,11]. A recent trial conducted in septic
patients, confirmed the potential of this approach in
reducing antibiotic use. Unfortunately this elegant study
focused on a population of patients that did not harbor
the most 'difficult to treat' strains, bypassing the problem
of multi-resistance.
Increasing serial PCT levels are associated with poor out-
comes in patients with severe infections [22,23]. Jensen et
al [24] demonstrated that when PCT increased the day fol-
lowing the first day after the blood level exceeded 1.0 ng/
mL, the 90-day mortality was significantly higher. Charles
et al found a significant decrease of PCT both between the
second and third day, as well as on the fourth day after the
onset of sepsis in a cohort of critically ill patients treated
with appropriate antibiotic therapy [25]. The small sam-
ple size of the present study does not allow any associa-
tion of PCT value with the appropriateness of therapy, but
our finding are compatible with other studies [24,25] that
demonstrate that a persistently high or increasing PCT
value is an ominous prognostic sign.
What does our study offer to the field? Prolonged ICU stay
is probably the most important determinant of ICU cost
[26]. An important proportion of critically ill patients
PCT values for patients with (constant line) and without  (dotted line) proven infection before and after the onset of  fever (D1) Figure 3
PCT values for patients with (constant line) and with-
out (dotted line) proven infection before and after 
the onset of fever (D1). PCT: Procalcitonin, D1: Day1 
(day of fever onset).
Table 3: Association between diagnostic markers and proven 
infection
Parameter OR 95% CI P
PCT > 0.5 8.6 2.4-31.0 0.001
CRP > 100 1.4 0.5-4.3 0.6
WBC > 12,000 9.7 2.3-40.8 0.001
SOFA > 7 5.4 1.6-18.0 0.006
PCT > 2 × D0 8.55 2.4-31.1 0.001
OR: Odds Ratio, CI: confidence interval, PCT: Procalcitonin, CRP: C - 
reactive protein, WBC: White Blood Cells, SOFA: Sequential Organ 
Failure Assessment.
Table 4: Validity of a four-fold increase of PCT value between 
day 1 (PCT1: day of fever onset) and the six previews days (PCT0 
to PCT-5) for differentiating patients with and without proven 
infection
Sensitivity Specificity PPV
PCT1-PCT0 59.26 86.95 84.20
PCT1-PCT(-1) 64 82.60 80
PCT1-PCT(-2) 68 77.27 77.27
PCT1-PCT (-3) 69.56 76.17 69.65
PCT1-PCT(-4) 66.67 80 77.77
PCT1-PCT(-5) 66.67 73.68 73.68
PPV: Positive Predictive Value, PCT: ProcalcitoninBMC Infectious Diseases 2009, 9:213 http://www.biomedcentral.com/1471-2334/9/213
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who survive their acute illness remain in a critical state
requiring intensive care management for weeks to
months. These patients are extremely prone to new infec-
tions both because they are constantly exposed to a high-
risk microbiological environment and because their
immune efficiency might be affected [27]. Furthermore
our clinical and laboratory tools for diagnosing sepsis
have been developed in different populations and have
not been validated in chronic critically ill patients, a pop-
ulation of patients that is expected to increase in future.
Although this study shows that PCT measurement can be
used as a useful marker of infection in this setting, the
introduction of PCT in the treatment algorithm of chronic
critically ill patients requires further studies. Hopefully
the ongoing intervention studies [28] will include a signif-
icant number of chronic critically ill patients, allowing
reliable conclusions. Another potentially important find-
ing of the study is that every PCT value taken during the
days preceding the advent of fever, and not only the pre-
vious day sample, carries potentially important predictive
value. This could mean that serial PCT values do not need
to be obtained on a daily basis, but twice or three times
weekly, a finding with obvious economic implications.
This study has certain limitations. It is a single-center
study in a population of chronically ill patients and this
could affect the generalization of the data, especially by
the time that practice of critical care in these populations
is not homogeneous and might have significant differ-
ences from site to site. Another limitation is that, almost
all of our chronic patients have been colonized with gram-
negative multi-resistant bacteria and the vast majority of
proven infections (25/27) were of Gram-negative origin.
Peak PCT response after Gram-negative challenge has
been found higher in vitro [29] as well as in vivo [30];
therefore the performance of PCT in populations of criti-
cally ill patients exposed to other microbial populations
should be investigated. Finally PCT values may not exclu-
sively be related to the underlying infection but to coexist-
ing organ failure as well; the small sample size of the study
does not allow a thorough analysis of this issue.
Conclusion
Serial serum PCT seems to be a marker capable of differ-
entiating chronic critically ill patients with manifested
infections compared to those presenting with fever of
non-infectious origin, demonstrating both diagnostic and
prognostic value. Although these observations support
the existing literature conducted in other selected popula-
tions, further studies in big number are needed to describe
the precise role of PCT in the management of these
extremely complicated cases.
Key messages
￿ PCT could differentiate patients with microbiologi-
cally proven sepsis among febrile critically ill patients
with prolonged ICU stay.
￿ A two-fold increase of PCT value between the day of
fever onset and the previous day is associated with
proven infection in febrile critically ill patients with
prolonged ICU stay.
￿ In chronic critically ill patients PCT performs better
than other widely used infection markers, such as CRP
and WBC count.
￿ PCT less than 0.5 ng/ml on the third day after the
advent of fever was associated with favorable survival
in febrile critically ill patients with prolonged ICU
stay.
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